Compare Merck & Co., Inc. (MRK) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Strategy Inc. — how do they compare? Merck & Co., Inc. trades at $146.49 (market cap $351.28B), while Strategy Inc. trades at $155.12 (market cap $60.40B). The key difference: Merck & Co., Inc. is far larger — about 5.8× Strategy Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Strategy Inc. for 112 Days on average.
| MRK | MSTR | |
|---|---|---|
Market Cap | $351.28B | $60.40B |
Volume | 7,969,665 | 23,421,830 |
Sector | Health | Technology |
52-Week High | $156.43 | $320.29 |
52-Week Low | $82.49 | $82.31 |
Typical Hold Time | 98 Days | 112 Days |
Enterprise Value | $398.04B | $79.16B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
MSTR stock trades at $155.91, up 1.66% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $3.85 billion in 2025 on $477.23 million in revenue, with a negative net income margin of -806.35%. Recent news highlights Bitcoin's price surge and Citigroup raising its price target to $240, though the stock has shown volatility around Bitcoin price movements.
The outlook is polarized: analyst consensus is bullish with a $253.36 price target, but fundamental risks are high due to persistent losses, negative cash flow from operations, and heavy debt. Investment opportunity hinges on Bitcoin's performance, while risks include earnings misses and financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
